DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
R• E••••••••• L••
Pharmaceuticals, Biotechnology and Life Sciencesgroup grade Aon a schedule nowsponsor unattributed
Also written as: LLC 1; LLC One; LLC Seventh Amendment
Principal held
at least $18.3M
sum of BDC pieces, a lower bound
Fair value
$19.7M
102c on cost, debt pieces
Unfunded
$652,000
commitments not yet drawn
BDC lenders
6
3 on the latest quarter
Facilities
5
1 equity pieces beside them
Next maturity
Oct 17, 2031
no dated debt inside 24 months
On the tape since
Dec 31, 2022
latest Jun 30, 2026
Events
5
dated, non-routine
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien | at least $16.3M | 102c | SOFR+525 bp | Oct 31, 2031 | 6 |
| first lien delayed draw term loan first lien | at least $1.1M | 101c | SOFR+500 bp | Oct 31, 2031 | 2 |
| first lien revolver first lien | at least $891,000 | 102c | SOFR+500 bp | Oct 31, 2031 | 2 |
| revolver lien unstated exited Dec 31, 2024 | unknown | n/a | unstated | 1 | |
| delayed draw term loan lien unstated exited Dec 31, 2024 | unknown | n/a | unstated | 1 |
Equity pieces beside the debt: equity ($1.4M fair value, 2 BDCs)
Lenders
every BDC piece at the latest quarter end
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| B•• I••••••••• C••• | term loan first lien F•••• L•••/S••••• S•••••• D••• I••••••• R••• 7.11% R•••••••• R••• and S••••• S••• + 5.25% | $2.6M | $2.6M 112c | SOFR+525 bp |
| C••••••• C•••••• B••• I••• | term loan first lien Investment T••• U••••••••• F•••• L••• T••• L••• I••••••• T••• S + 500, 75 F•••• I••••••• R | $862,000 | $861,000 101c | SOFR+500 bp |
| C••••••• C•••••• B••• I••• | delayed draw term loan first lien Investment T••• U••••••••• F•••• L••• D•••••• D••• T••• L••• I••••••• T••• S + 500, 75 F•• | $630,000 | $628,000 101c | SOFR+500 bp |
| C••••••• C•••••• B••• I••• | delayed draw term loan first lien Investment T••• D•••••• D••• T••• L••• C••••••••• E••••••••• D••• 10/17/2031 | n/a | n/a | |
| C••••••• C•••••• B••• I••• | revolver first lien Investment T••• U••••••••• F•••• L••• R••••••• I••••••• S + 500, 75 F•••• I••••••• R••• 8. | $495,000 | $493,000 102c | SOFR+500 bp |
| C••••••• C•••••• B••• I••• | term loan first lien Investment T••• U••••••••• F•••• L••• T••• L••• I••••••• T••• S + 500, 75 F•••• I••••••• R | $6.8M | $6.7M 101c | SOFR+500 bp |
| C••••••• C•••••• B••• I••• | equity equity Investment T••• C••••• S•••• | n/a | $786,000 99c | |
| C••••••• C•••••• B••• I••• | revolver first lien Investment T••• R••••••• C••••••••• E••••••••• D••• 10/17/2031 | n/a | n/a | |
| C••••••• P•••••• C••••• I••••• C••• | revolver first lien Investment T••• R••••••• E••••••••• D••• 10/17/2031 | n/a | n/a | |
| C••••••• P•••••• C••••• I••••• C••• | equity equity Investment T••• C••••• S•••• | n/a | $629,000 99c | |
| C••••••• P•••••• C••••• I••••• C••• | term loan first lien Investment T••• U••••••••• F•••• L••• T••• L••• I••••••• T••• S + 525, 75 F•••• I••••••• R | $690,000 | $689,000 101c | SOFR+525 bp |
| C••••••• P•••••• C••••• I••••• C••• | delayed draw term loan first lien Investment T••• D•••••• D••• T••• L••• E••••••••• D••• 10/17/2026 | n/a | n/a | |
| C••••••• P•••••• C••••• I••••• C••• | delayed draw term loan first lien Investment T••• U••••••••• F•••• L••• D•••••• D••• T••• L••• I••••••• T••• S + 500, 75 F•• | $504,000 | $502,000 101c | SOFR+500 bp |
| C••••••• P•••••• C••••• I••••• C••• | revolver first lien Investment T••• U••••••••• F•••• L••• R••••••• I••••••• T••• S + 500, 75 F•••• I••••••• R• | $396,000 | $395,000 102c | SOFR+500 bp |
| C••••••• P•••••• C••••• I••••• C••• | term loan first lien Investment T••• U••••••••• F•••• L••• T••• L••• I••••••• T••• S + 525, 75 F•••• I••••••• R | $5.4M | $5.4M 101c | SOFR+525 bp |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 3 | $18.3M | $18.3M | 102c | 0 |
| Mar 31, 2026 | 3 | $9.4M | $9.5M | 104c | 0 |
| Dec 31, 2025 | 3 | $8.9M | $8.9M | 104c | 0 |
| Sep 30, 2025 | 3 | $9.0M | $9.0M | 105c | 0 |
| Jun 30, 2025 | 2 | $6.4M | $6.5M | 103c | 0 |
| Mar 31, 2025 | 3 | $16.7M | $16.5M | 100c | 0 |
| Dec 31, 2024 | 3 | $7.9M | $7.7M | 100c | 0 |
| Sep 30, 2024 | 3 | $8.5M | $8.5M | 100c | 0 |
| Jun 30, 2024 | 2 | $3.5M | $3.4M | 98c | 0 |
| Mar 31, 2024 | 3 | $8.6M | $8.4M | 99c | 0 |
| Dec 31, 2023 | 3 | $8.5M | $8.4M | 100c | 0 |
| Sep 30, 2023 | 2 | $3.4M | $3.4M | 99c | 0 |
| Jun 30, 2023 | 2 | $3.5M | $3.4M | 100c | 0 |
| Mar 31, 2023 | 2 | $2.0M | $1.9M | 100c | 0 |
| Dec 31, 2022 | 2 | $2.9M | $2.9M | 100c | 0 |
What changed
- Marked down (one lender)Mar 31, 2026
- New lender joined a facilitySep 30, 2025
- New lender joined a facilityMar 31, 2025
- Spread changed (observed)Dec 31, 2024
- Maturity extended (observed)Dec 31, 2024
- New lender joined a facilityDec 31, 2024
- Facility left every BDC scheduleDec 31, 2024
- Facility left every BDC scheduleDec 31, 2024
- Maturity extended (observed)Dec 31, 2024
- Lender left a facilitySep 30, 2024
- Lender left a facilitySep 30, 2024
- New lender joined a facilityDec 31, 2023
- New borrower on a BDC scheduleDec 31, 2022
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- RN ENTERPRISEderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 6 BDCsderived
- Industry
- Pharmaceuticals, Biotechnology and Life Sciencesreportedas one filer wrote it